NCT06564324Phase 3Recruiting

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2029-01Estimated

Enrollment · participants194Estimated

Source updated2026-04-13Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-13 · 1 field changed

Planned enrollment increased by 56 participants

− Before

~~138 participants (planned)~~

+ After

194 participants (planned)

Check registry source